Ignite Creation Date:
2025-12-24 @ 5:58 PM
Ignite Modification Date:
2026-03-06 @ 2:31 PM
Study NCT ID:
NCT01911468
Status:
COMPLETED
Last Update Posted:
2013-07-30
First Post:
2013-07-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin
Sponsor:
University Medical Centre Ljubljana
Organization:
Study Overview
Official Title:
Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin
Status:
COMPLETED
Status Verified Date:
2013-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to determine whether combined treatment with liraglutide and metformin is more effective than liraglutide or metformin as monotherapy in the treatment of obese women with polycystic ovary syndrome (PCOS) who had been previously poor responders regarding weight reduction on metformin monotherapy. We anticipated greater changes in body weight in patients on combined treatment than in those on monotherapy with liraglutide or metformin.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: